However, despite the difficulty in discerning the causality link between MIF modulation and neuroblastoma phenotype upon vorinostat, it should be pointed out that identifying drugs, already approved for clinical use, that are able to modulate MIF and DDT, is particularly important as MIF-targeted therapies are still in preclinical or in very early clinical development. Here, MIF is linked to neuroblastoma.